Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis - PubMed
5 hours ago
- #Psilocybin
- #Meta-Analysis
- #Major Depressive Disorder
- Standard-dose psilocybin (25 mg/session) showed significant efficacy in reducing depressive symptoms compared to control groups.
- Standard-dose psilocybin was associated with higher response and remission rates at 2-3 weeks post-treatment, and sustained response at 6-12 weeks.
- Standard-dose psilocybin had lower all-cause discontinuation rates compared to controls.
- Common side effects included headache and nausea, but these resolved after 1-9 days post-treatment.
- Low-dose psilocybin (10 mg/session) did not show superior efficacy compared to control groups.
- The meta-analysis highlights the potential of standard-dose psilocybin as a therapeutic option for major depressive disorder (MDD).
- Future research should address methodological heterogeneity across current trials.